The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia

Archives of General Psychiatry

Volumn 54, Issue 6, 1997, Pages 567-572

  Kramer, Mark S ^a,b   Last, Barbara ^a   Getson, Albert ^a   Reines, Scott A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; CHLORAL HYDRATE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; LORAZEPAM; PLACEBO; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR; DRD4 PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MENTAL DISEASE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; ACUTE DISEASE; DRUG COMBINATION; HOSPITALIZATION; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; CHLORAL HYDRATE; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; LORAZEPAM; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031159043     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830180085011     Document Type: Article

References (21)

1. Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
2. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
3. 4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991;350:610-614.
4. 4 receptors elevated in schizophrenia. Nature. 1993;365:441-445.
5. 4 receptors in Parkinson's, schizophrenia, and control brain striata. Synapse. 1993;14:247-253.
6. 125I]epidepride. Eur J Pharmacol. 1995;286:R3-R5.
7. 3H]nemonapride. J Neurochem. 1995;64:1413-1415.
8. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 1995;681:109-116.
9. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci. 1995;15(pt 2):2186-2191.
10. 4 receptors increased in schizophrenia? J Neurochem. 1994;63:1576-1577.
11. 4 receptor. J Pharmacol Exp Ther. In press.
12. 4 receptor antagonist, L-745,870, on amphetamine-induced behaviors in rodents. Br J Pharmacol. 1996;119:210-212.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
14. Overall JE. The Brief Psychiatric Rating Scale in psychopharmacology research. Pharmacopsychiatry. 1974;7:67-78.
15. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull. 1988;24:112-114.
16. Simpson GM, Angus JSW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212(suppl):11-19.
17. Opler LA, Kay SR, Rosado V, Lindenmayer JP. Positive and negative syndromes in chronic schizophrenic inpatients. J Nerv Ment Dis. 1984;172:317-325.
18. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual. Rockville, Md: US Dept of Health and Human Services; 1976:218-222. US Dept of Health and Human Services publication (ADM) 91-338.
19. 4 receptor antagonist. Br J Pharmacol. 1996;119(suppl):29P.
20. 2-family receptor distribution in human post-mortum tissue: an autoiradiographic study. Neuroreport. 1995;6:2505-2512.
21. Kane J. Conduct of studies: II. Presented at a Food and Drug Administration Advisory Committee Meeting on the Development of Antipsychotic Medications; July 25, 1995; Gaithersburg, Md.